clinical outcomes of ultrathin strut biodegradable polymer-coated everolimus-eluting stent in patients with coronary artery disease

Background: evermine 50™ (meril life sciences pvt. ltd., india) everolimus-eluting stent system (ees) is a novel ultrathin strut (50 μm) cobalt-chromium coronary drug-eluting stent (des) platform with biodegradable polymer coating. the evermine 50 ees-kles study aimed to evaluate the evermine 50 ees in terms of 24-month clinical safety and performance in patients with coronary artery disease (cad). methods: this retrospective study consisted of 171 patients (258 lesions) implanted with evermine 50 ees for managing cad. we analyzed the major adverse cardiac events (mace) incidence, defined as a composite of cardiac death, myocardial infarction, and ischemia-driven target lesion revascularization (id-tlr) at 6-, 12-, and 24-month follow-up. results: a total of 171 patients were included with a mean age of 57.85 ± 10.05 years, of which, 139 (81.29%) were men, 69 (40.35%) were hypertensive, and 70 (40.94%) were diabetic. the incidence of mace was 1 (0.58%), 3 (1.81%), and 4 (2.42%) at 6-, 12-, and 24-month follow-up, respectively. there were three cases (1.82%) of cardiac death and one case (0.61%) of id-tlr up to 24 months. none of the patients was presented with definite or probable stent thrombosis (st). conclusion: this study demonstrated that implantation of ultrathin strut evermine 50 ees resulted in a low rate of incidence of mace, indicating a favourable clinical safety and performance profile of evermine 50 ees in patients with cad [clinical trials registry-india (ctri) number: ctri/2017/09/009939)].